Breaking Medical News and In Depth Medical Stories

Search News:
Treating diabetic macular edema (DME) with ranibizumab
Treating diabetic macular edema (DME) with ranibizumab (May 15, 2015 - Insidermedicine)
From Pennsylvania - Research published in Ophthalmology examines the cost-effectiveness of treating diabetic macular edema with ranibizumab. Researchers reviewed data from the RISE and RIDE clinical trials. They performed cost-utility analysis associated with intravitreal ranibizumab vs. sham therapy for diabetic macular edema. Researchers measured quality-adjusted life years (QALY) in patients as well the cost-utility ratio, measured as $/QALY. Results showed that 14 year incremental patient value gain resulting from the treatment equated to an 11% improvement in quality of life. After accounting for direct medical costs that were saved from the treatment, researchers found that use of this therapy conferred significant gain to the patient and resulted in a financial value gain.